Stock number one is:
Isis Pharmaceuticals Inc., (SYMBOL: ISIS) and the headline says: Biogen Expands Isis Partnership in $100 Million Drug Deal -- Bloomberg
Isis Pharmaceuticals will receive $100 million from Biogen Idec in a six-year agreement to develop treatments for neurological disorders, and up to $220 million thereafter for each new drug compound. This marks the fourth recent collaboration between the companies, which is expected to bring new drugs to market annually beginning next year.
Isis is a small-cap aggressive growth company which typically takes a net loss every year.
The share price shot up to the low $30’s this summer, then corrected. The stock could appeal to traders while it ranges between $28 and $34 in the near-term.
Our Ransom Note trendline says: BUY ISIS PHARMACEUTICALS AT $28.
Stock number two is:
Crown Castle International Corp., (SYMBOL: CCI) and the headline says: S&P REITERATES STRONG BUY OPINION ON SHARES OF CROWN CASTLE – S&P
Crown Castle, operator of wireless towers and infrastructure, has begun the process of reorganizing as a Real Estate Investment Trust. REIT’s typically pay substantial dividends to shareholders. The company has not yet commented on future payouts, but S&P recently said, “We view the shares as highly attractive, given our expectations for strong free cash flow growth.”
The company became profitable in 2011, and generally expects rapid annual earnings growth.
The stock has been trading between $67 and $81 all year. Crown Castle shares could appeal to growth & income investors and traders for the future dividend and the wide trading range.
Our Ransom Note trendline says..... ACCUMULATE CROWN CASTLE UNDER $72.
Stock number three is:
Healthcare Solutions Begin with Innovators in Tennessee, Not Bureaucrats in Washington, DC | Congressman Marsha Blackburn